What changed in Waters Corporation's latest annual report
In the year ended 31 Dec 2025, Waters Corporation's revenue rose 7% to USD 3.17bn, from USD 2.96bn; net income rose 0.8% to USD 642.63m, from USD 637.83m; cash and cash equivalents rose 80.7% to USD 587.83m, from USD 325.36m.
Year ended 31 Dec 2025. Source: 10-K filed 23 Feb 2026, read it on SEC EDGAR.
USD 2.96bn to USD 3.17bn
The figures, year on year
| Item | Year before | Latest year | Change |
|---|---|---|---|
| Revenue | 2.96bn | 3.17bn | Up 7% |
| Net income | 637.83m | 642.63m | Up 0.8% |
| Total assets | 4.55bn | 5.08bn | Up 11.5% |
| Total liabilities | 2.73bn | 2.52bn | Down 7.7% |
| Long-term debt | 1.63bn | 947.45m | Down 41.7% |
| Cash and cash equivalents | 325.36m | 587.83m | Up 80.7% |
| Shareholders' equity | 1.83bn | 2.56bn | Up 40.1% |
Questions people ask
Did Waters Corporation's revenue grow last year?
Revenue grew 7%, from USD 2.96bn to USD 3.17bn in the year ended 31 Dec 2025.
Is Waters Corporation profitable?
Yes. Net income was USD 642.63m in the year ended 31 Dec 2025. The year before: USD 637.83m.
How much cash and debt does Waters Corporation have?
At its latest year end (31 Dec 2025), Waters Corporation reported cash and cash equivalents of USD 587.83m and long-term debt of USD 947.45m.
Where do these numbers come from?
From Waters Corporation's own annual filings with the SEC. Each change is calculated from the reported figures; nothing is estimated.
Meeting a client who works with Waters Corporation?
LYNORIQ remembers every client meeting the way this page tracks a filing: what changed since last time, what you promised, and what they owe you.
Start free See the demoOther Laboratory Analytical Instruments companies
- Agilent Technologies, Inc.Cash and cash equivalents up 34.6%
- Illumina, Inc.Shareholders' equity up 14.7%
- Mettler-Toledo International Inc.Total assets up 14.6%
- Revvity, IncCash and cash equivalents down 20.9%
- Avantor, Inc.Cash and cash equivalents up 39.5%
- 10x Genomics, Inc.Total liabilities up 17.5%
- Bio-Rad Laboratories, Inc.Shareholders' equity up 13.5%